In a preclinical mesothelioma model, dual blockade with anti-PD-L1 and anti-LAG-3 delayed tumor growth and improved survival compared with controls, although the combination did not outperform anti-PD-L1 monotherapy [114]. Here, LAG3 is linked to mesothelioma.